Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Prospectus Sup

<< Previous

Bullboard Posts

Next >>

Post by palinc2000on Jul 26, 2021 6:38am

203 Views

Post# 33603238

Prospectus Sup

Now available.... 33 pages long
Had a quick read thru....Costs estimated at 600000$ not including the 3% fee on the gross proceed payable to Cantor ...ie 1.5 million$ if they end up issuing the full 50 million$

<< Previous

Bullboard Posts

Next >>

Boeing workers end strike, return to work